| Author | Picot, Stephane | |
| Author | Marty, Aileen | |
| Author | Bienvenu, Anne-Lise | |
| Author | Blumberg, Lucille H. | |
| Author | Dupouy-Camet, Jean | |
| Author | Carnevale, Pierre | |
| Author | Kano, Shigeyuki | |
| Author | Jones, Malcolm K. | |
| Author | Ribeiro, Claudio Tadeu Daniel | |
| Author | Mas-Coma, Santiago | |
| Access date | 2022-03-08T12:09:14Z | |
| Available date | 2022-03-08T12:09:14Z | |
| Document date | 2020 | |
| Citation | PICOT, Stephane et al. Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19. One Health, v. 9, 100131, p. 1-5, 2020. | pt_BR |
| ISSN | 2352-7714 | pt_BR |
| URI | https://www.arca.fiocruz.br/handle/icict/51608 | |
| Description | Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. | pt_BR |
| Language | eng | pt_BR |
| Publisher | Elsevier | pt_BR |
| Previous version | https://www.arca.fiocruz.br/handle/icict/40858 | pt_BR |
| Rights | open access | |
| Subject in Portuguese | COVID-19 | pt_BR |
| Subject in Portuguese | SARS-CoV-2 | pt_BR |
| Subject in Portuguese | Cloroquina | pt_BR |
| Subject in Portuguese | Hidroxicloroquina | pt_BR |
| Subject in Portuguese | Lúpus Eritematoso Sistêmico | pt_BR |
| Subject in Portuguese | Imunomodulação | pt_BR |
| Subject in Portuguese | Coronavírus | pt_BR |
| Subject in Portuguese | Malária | pt_BR |
| Subject in Portuguese | Antiviral | pt_BR |
| Title | Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19 | pt_BR |
| Type | Article | |
| DOI | 10.1016/j.onehlt.2020.100131 | |
| Abstract | Our coalition of public health experts, doctors, and scientists worldwide want to draw attention to the need for
high-quality evaluation protocols of the potential beneficial effect of hydroxychloroquine (HCQ) as a post-exposure
drug for exposed people. In the absence of an approved, recognized effective pre or post-exposure prophylactic
drug or vaccine for COVID-19, nor of any approved and validated therapeutic drug, coupled with social
and political pressure raised by publicity both regarding the potential beneficial effect of hydroxychloroquine
(HCQ) as well as potential risks from HCQ, we urge the immediate proper clinical trials. Specifically, we mean
using HCQ for post-exposure of people with close contact with patients with positive COVID19 rtPCR, including
home and medical caregivers. We have reviewed the mechanisms of antiviral effect of HCQ, the risk-benefit ratio
taking into consideration the PK/PD of HCQ and the thresholds of efficacy. We have studied its use as an
antimalarial, an antiviral, and an immunomodulating drug and concluded that the use of HCQ at doses matching
that of the standard treatment of Systemic Lupus erythematous, which has proven safety and efficacy in terms of
HCQ blood and tissue concentration adapted to bodyweight (2,3), at 6 mg/kg/day 1 (loading dose) followed by 5
mg/kg/ day, with a maximum limit of 600 mg/day in all cases should swiftly be clinically evaluated as a postexposure
drug for exposed people. | pt_BR |
| Affilliation | Malaria Research Unit, ICBMS, UMR 5246, CNRS, INSA, CPE University Lyon, 69100 Villeurbanne, France / Institute of Parasitology and Medical Mycology, Croix-Rousse Hospital, Hospices Civils de Lyon. 69004 Lyon, France. | pt_BR |
| Affilliation | Translational Medicine, HWCOM, FIU Health Travel Medicine Program and Vaccine Clinic Commander, Emergency Response Team Development. Miami, FL, USA. | pt_BR |
| Affilliation | Malaria Research Unit, ICBMS, UMR 5246, CNRS, INSA, CPE University Lyon, 69100 Villeurbanne, France / Groupement Hospitalier Nord, Service Pharmacie, Hospices Civils de Lyon, 69004 Lyon, France. | pt_BR |
| Affilliation | Division of Public Health Surveillance and Response, National Institute for Communicable Diseases, 2131. Johannesburg, South Africa. | pt_BR |
| Affilliation | Faculté de Médecine Paris Descartes, Académie Vétérinaire de France. Paris, France. | pt_BR |
| Affilliation | Institute of Research for Development (former), Montpellier Centre. BP 64501, 34394 Montpellier, France. | pt_BR |
| Affilliation | Department of Tropical Medicine and Malaria, Research Institute, National Center for Global Health and Medicine. Tokyo 162-8655, Japan. | pt_BR |
| Affilliation | School of Veterinary Science, The University of Queensland. Brisbane, QLD, Australia. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Pesquisa em Malária. Rio de Janeiro, RJ, Brasil. | pt_BR |
| Affilliation | Departamento de Parasitología, Facultad de Farmacia, Universidad de Valencia. 46100, Valencia, Spain. | pt_BR |
| Subject | COVID-19 | pt_BR |
| Subject | SARS-CoV-2 | pt_BR |
| Subject | Chloroquine | pt_BR |
| Subject | Hydroxychloroquine | pt_BR |
| Subject | Systemic lupus erythematosus | pt_BR |
| Subject | Immunomodulation | pt_BR |
| Subject | Coronavirus | pt_BR |
| Subject | Malaria | pt_BR |
| Subject | Antiviral | pt_BR |
